AtriCure Reports First Quarter 2024 Financial Results

Rhea-AI Summary

AtriCure, Inc. reported first-quarter 2024 financial results, with worldwide revenue of $108.9 million, a 16.4% increase year over year. The U.S. revenue was $90.2 million, up 15.4% from first quarter 2023. International revenue increased by 21.5% to $18.6 million. Gross profit was $81.3 million with a gross margin of 74.7%. Loss from operations was $10.9 million. Adjusted EBITDA was $2.8 million. Full-year 2024 revenue is projected to be $459 million to $466 million, with adjusted EBITDA expected to be $26 million to $29 million.

Positive

• Revenue increased by 16.4% year over year, reflecting global adoption of products.

• U.S. revenue grew by 15.4%, driven by key product lines like Hybrid AF™ Therapy procedures and AtriClip® Flex·V® device.

• International revenue saw a robust increase of 21.5%.

• Gross profit was $81.3 million with a gross margin of 74.7%, showing improvement from the previous year.

• Adjusted EBITDA increased to $2.8 million.

Negative

• Loss from operations increased to $10.9 million, impacted by the absence of a $4.0 million gain from legal settlement in 2023.

• Basic and diluted net loss per share was $0.28, higher than $0.14 in the first quarter of 2023.

• Adjusted loss per share for the first quarter 2024 was $0.25, compared to $0.23 for the first quarter 2023.

Insights

Financial Analyst

AtriCure's report of a 16.4% year-over-year revenue increase to $108.9 million in the first quarter of 2024 signifies a robust adoption rate of their products, which indicates a strong market position and growing demand. Particularly noteworthy is the 15.4% growth in the U.S. market, driven by key product lines like the EPi-Sense System and the AtriClip Flex·V device. However, investors should consider the mixed financial signals, such as the 21 basis point increase in gross margin tempered by a higher loss from operations and a doubling of net loss per share from $0.14 to $0.28, likely influenced by the absence of a legal settlement gain compared to 2023. The projection of a 15% to 17% revenue increase for the full year 2024, alongside a significant expected growth in adjusted EBITDA, suggests confidence in continued performance improvement. However, the anticipated increase in adjusted loss per share warrants attention to the company's cost management and potential investment in future growth.

Market Research Analyst

The market's response to AtriCure's international expansion, with a 21.5% increase in international revenue, underscores the importance of global diversification. Given that the medical device industry often faces stringent regulatory hurdles, this expansion is an indicator of AtriCure's agility and compliance proficiency. The emphasis on their diversified product portfolio, including the sales of the EPi-Sense System and cryoSPHERE probe, reflects a strategic move to mitigate risks associated with product-specific demand fluctuations. AtriCure's R&D investments, signaled by their commitment to launching new products and advancing clinical research, positions them well for future innovation and competitive differentiation. However, investors should be cautious of the challenges that come with rapid expansion, such as potential supply chain issues, regulatory obstacles and the need for increased marketing and sales expenditures to capture market share.

Healthcare Industry Analyst

The surge in demand for AtriCure's Afib treatment products, particularly in light of the growing global Afib patient population, suggests a favorable outlook on the company's market proposition. The FDA approval of their Isolator Synergy Ablation System for persistent Afib treatment exemplifies AtriCure's leadership in the field. It's also worth noting the strategic importance of AtriCure's advanced therapies, such as the Hybrid AF Therapy, in the broader context of minimally invasive surgical innovations, which are increasingly favored over traditional open-heart procedures. This trend could offer tailwinds for AtriCure's future growth. However, the pressure on minimally invasive appendage management products, highlighted by the decline in LARIAT system sales, raises questions about the sustainability of growth in this segment and may signal a need for strategic reassessment.

• Worldwide revenue of $108.9 million – an increase of 16.4% year over year

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results.

“We are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “We remain diligently focused on expanding the reach of our solutions for patients with advanced forms of Afib, managing the LAA in patients undergoing cardiac surgery and reducing post-operative pain. To that end, we look forward to advancing our clinical research initiatives and launching several new products this year.”

First Quarter 2024 Financial Results

Revenue for the first quarter 2024 was $108.9 million, an increase of 16.4% over first quarter 2023 revenue (16.3% on a constant currency basis), reflecting continuing adoption of our products by physicians globally. On a sequential basis, worldwide revenue for the first quarter 2024 increased approximately 2.2% from the fourth quarter 2023.

U.S. revenue was $90.2 million, an increase of $12.1 million or 15.4%, compared to the first quarter 2023. U.S. revenue growth was driven by sales across key product lines, highlighted by Hybrid AF™ Therapy procedures using the EPi-Sense System in minimally invasive ablation, the ENCOMPASS^® clamp in open ablation, the AtriClip^® Flex·V^® device in appendage management, and the cryoSPHERE^® probe for post-operative pain management. U.S. revenue growth was partially offset by pressure in minimally invasive appendage management products, primarily from a decline in the LARIAT^® system sales. International revenue increased $3.3 million or 21.5% (21.1% on a constant currency basis) to $18.6 million, with robust activity across all franchises and geographic regions.

Gross profit for the first quarter 2024 was $81.3 million compared to $69.6 million for the first quarter 2023. Gross margin was 74.7% for the first quarter 2024, showing improvement of 21 basis points from the first quarter 2023 and reflecting more favorable product and geographic mix. Loss from operations for the first quarter 2024 was $10.9 million, compared to $5.8 million for the first quarter 2023, driven by the $4.0 million gain from legal settlement in 2023. Basic and diluted net loss per share was $0.28 for the first quarter 2024, compared to $0.14 for the first quarter 2023.

Adjusted EBITDA for the first quarter 2024 is $2.8 million, an increase of $0.9 million over first quarter of 2023. Adjusted loss per share for the first quarter 2024 was $0.25, compared to $0.23 for the first quarter 2023.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release.

2024 Financial Guidance

Full year 2024 revenue is projected to be approximately $459 million to $466 million, reflecting growth of approximately 15% to 17% over full year 2023. Management continues to expect full year 2024 Adjusted EBITDA of approximately $26 million to $29 million, with improvements annually thereafter. Full year 2024 adjusted EBITDA represents an approximately 34% to 49% increase over full year 2023. Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.82.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024 to discuss first quarter 2024 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly known as Twitter) @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of May 1, 2024. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible assets, debt extinguishment and legal settlements. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited)
	Three Months Ended March 31,
		2024				2023
United States Revenue:
Open ablation	$	29,300			$	25,142
Minimally invasive ablation		12,318				9,637
Pain management		12,739				11,068
Total ablation		54,357				45,847
Appendage management		35,892				32,342
Total United States		90,249				78,189
International Revenue:
Open ablation		7,902				7,286
Minimally invasive ablation		2,114				1,867
Pain management		937				228
Total ablation		10,953				9,381
Appendage management		7,649				5,924
Total International		18,602				15,305
Total revenue		108,851				93,494
Cost of revenue		27,583				23,885
Gross profit		81,268				69,609
Operating expenses:
Research and development expenses		19,845				15,327
Selling, general and administrative expenses		72,340				60,064
Total operating expenses		92,185				75,391
Loss from operations		(10,917	)			(5,782	)
Other expense, net		(2,169	)			(616	)
Loss before income tax expense		(13,086	)			(6,398	)
Income tax expense		183				78
Net loss	$	(13,269	)		$	(6,476	)
Basic and diluted net loss per share	$	(0.28	)		$	(0.14	)
Weighted average shares used in computing net loss per share:
Basic and diluted		46,719				46,107

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited)
	March 31, 2024				December 31, 2023
Assets
Current assets:
Cash, cash equivalents, and short-term investments	$	105,957			$	137,285
Accounts receivable, net		55,319				52,501
Inventories		71,945				67,897
Prepaid and other current assets		12,004				8,563
Total current assets		245,225				266,246
Property and equipment, net		42,035				42,435
Operating lease right-of-use assets		4,199				4,324
Goodwill and intangible assets, net		296,904				298,767
Other noncurrent assets		3,265				2,160
Total Assets	$	591,628			$	613,932
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	58,710			$	72,036
Current maturities of lease liabilities		2,542				2,533
Total current liabilities		61,252				74,569
Long-term debt		61,865				60,593
Finance and operating lease liabilities		10,956				11,368
Other noncurrent liabilities		1,242				1,234
Total Liabilities		135,315				147,764
Stockholders' Equity:
Common stock		48				48
Additional paid-in capital		827,288				824,170
Accumulated other comprehensive loss		(697	)			(993	)
Accumulated deficit		(370,326	)			(357,057	)
Total Stockholders' Equity		456,313				466,168
Total Liabilities and Stockholders' Equity	$	591,628			$	613,932

ATRICURE, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS
(In Thousands)
(Unaudited)
Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)
	Three Months Ended March 31,
		2024				2023
Net loss, as reported	$	(13,269	)		$	(6,476	)
Income tax expense		183				78
Other expense, net		2,169				616
Depreciation and amortization expense		4,452				2,943
Share-based compensation expense		9,265				8,760
Gain from legal settlement		—				(4,000	)
Non-GAAP adjusted income (adjusted EBITDA)	$	2,800			$	1,921

	Three Months Ended March 31,
		2024				2023
Net loss, as reported	$	(13,269	)		$	(6,476	)
Loss on debt extinguishment		1,362				—
Gain from legal settlement		—				(4,000	)
Non-GAAP adjusted net loss	$	(11,907	)		$	(10,476	)
Basic and diluted adjusted net loss per share	$	(0.25	)		$	(0.23	)
Weighted average shares used in computing adjusted net loss per share
Basic and diluted		46,719				46,107

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501709797/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Marissa Bych

Gilmartin Group

Investor Relations

(415) 937-5402

marissa@gilmartinir.com

Source: AtriCure, Inc

FAQ

What was AtriCure's worldwide revenue for the first quarter of 2024?

AtriCure reported worldwide revenue of $108.9 million for the first quarter of 2024, representing a 16.4% increase year over year.

How much was the U.S. revenue for AtriCure in the first quarter of 2024?

AtriCure's U.S. revenue in the first quarter of 2024 was $90.2 million, up by 15.4% compared to the same period in 2023.

What is AtriCure's projected revenue range for full-year 2024?

AtriCure projects full-year 2024 revenue to be approximately $459 million to $466 million, reflecting a growth of 15% to 17% over full year 2023.

What was AtriCure's gross profit for the first quarter of 2024?

AtriCure's gross profit for the first quarter of 2024 was $81.3 million with a gross margin of 74.7%.

What was the adjusted EBITDA for AtriCure in the first quarter of 2024?

AtriCure's adjusted EBITDA for the first quarter of 2024 was $2.8 million, showing an increase over the same period in 2023.